Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Financial disclosure(s)
- Severe exacerbations in clinical trials
- Hypotheses
- Objectives
- Clinical trials to develop CompEx Asthma (1)
- Clinical trials to develop CompEx Asthma (2)
- Patient characteristics of development trials
- Patient characteristics of the test trials
- Methodology to build diary events
- Example of a diary event (Threshold)
- Example of a diary event (Slope)
- Definition of a CompEx Asthma event
- CompEx Asthma & severe exacerbations
- CompEx Asthma algorithm for event frequency
- CompEx Asthma algorithm for treatment effect
- CompEx Asthma algorithm for sample size
- CompEx Asthma events increase
- CompEx Asthma treatment effect
- Sample size is reduced by ~50%
- CompEx Asthma mirrors the exacerbations
- Properties of severe exacerbations & CompEx
- CompEx Asthma trials (AZ6 & 7)
- CompEx Asthma trials (AZ8 & 9)
- CompEx Asthma trials (GSK1, 2, & 3)
- Conclusions
- Acknowledgements
Topics Covered
- A composite/surrogate endpoint for asthma severe exacerbations (CompEx)
- Predicting treatment efficacy on asthma severe exacerbations with CompEx
- Overview of clinical trials used to develop CompEx asthma
- Methodology to build diary events
- Definition of a CompEx Asthma event
- CompEx asthma algorithms
- CompEx asthma performance vs. severe exacerbations
- Acceleration of clinical development through CompEx asthma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Da Silva, C.A. (2019, August 29). CompEx asthma: a novel composite exacerbation endpoint [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/ITDV9460.Export Citation (RIS)
Publication History
Financial Disclosures
- This work was funded by AstraZeneca. Carla A. Da Silva is a full-time employee of AstraZeneca.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I am Carla Da Silva and I work at
AstraZeneca as a Senior Principal Medical Scientist.
It is my pleasure today to be presenting the recent work performed on CompEx,
a novel Composite Exacerbation Endpoint in Asthma
to accelerate clinical development.
0:19
The work presented today was funded by
AstraZeneca, and I am a full-time employee of AstraZeneca.
0:27
Why are asthma severe exacerbations of importance?
They are important since their prevention is a key goal of treatment.
To help standardize across clinical trials,
The American Thoracic Society and
European Respiratory Society have provided a definition of severe exacerbations.
These are defined as
worsening of symptoms leading to the use of
systemic steroids and hospital admission or an emergency room visit
because of asthma requiring systemic steroids.
As defined, severe exacerbations are rare events with
annualized rates ranging from 0.2 exacerbations a year in mild asthmatics,
to 1.1 exacerbations a year for severe asthmatics.
As a consequence, clinical trials using severe exacerbation as the primary outcome are
lengthy and require large sample sizes to have
sufficient power to show differences between interventions.
That is why they are conventionally not studied until later in
6,12, and sometimes 18-month Phase 3 trials.
1:30
We, therefore, hypothesized that extending the definition of a severe exacerbation,
to include subjective measures of asthma worsening that are of clinical relevance,
should increase event rates.
Therefore, this will provide insight into the evaluation of novel and existing therapies,
not only in Phase 2,
but also in Phase 3 trials.
Additionally, the development of a tool that
predicts the effect of treatments on severe exacerbations
with reduced sample size and trial duration,
might enable more efficient drug development and approval,
bringing new drugs to market faster to asthmatic patients who need them.